Nostrum Biodiscovery celebrates its 10th anniversary, recognising its continued growth and advances in molecular design
Nostrum Biodiscovery marks ten years of growth and scientific innovation, celebrating its global presence and a portfolio of technologies designed to accelerate drug discovery.
Founded in 2015, Nostrum Biodiscovery is a spin-off of the Barcelona Supercomputing Center, the Institute for Research in Biomedicine of Barcelona, the University of Barcelona, and ICREA. Today, it marks a 10-year milestone after a decade of expansion and technological evolution. With more than 150 completed projects and collaborations with four of the world’s top ten pharmaceutical companies, Nostrum Biodiscovery has established itself as a leading partner in computational drug discovery.
Throughout this decade, Nostrum has broadened its molecular modeling capabilities and technology across protein engineering, nucleic acid design, immunology, small molecules, and targeted protein degradation, including the release of its proprietary platform Nostrum-Suite®. By integrating physics-based simulation, advanced AI models, and high-performance computing, Nostrum Biodiscovery enables structure-guided design and accelerates discovery programs, reducing experimental load.
In 2025, the company opened a new office at the Cambridge Innovation Center in Boston, strengthening its international activity and supporting partners in the US biotech ecosystem.
Reaching the break-even point in 2020 and operatIng without additional fundraising, Nostrum’s trajectory highlights a model of sustainable growth driven by scientific expertise and excellence.